In two identical phase 3 trials of 1,227 adults with moderate to severe hidradenitis suppurativa, oral povorcitinib 45 or 75 mg raised week-12 HiSCR50 vs placebo (40–42% vs 30% and 29%). Serious adverse events: 5–6% by week 54; acne was common (17–20%).
RCTn = 1,227
Porter et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials